PROVENGE^® Autologous Cellular Immunotherapy

PROVENGE^® (sipuleucel-T) is the first in a new therapeutic class known as autologous cellular immunotherapies. PROVENGE^® was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormonerefractory) prostate cancer and is made by Dendreon Corporation.

PROVENGE^® is an autologous (made from a patient’s own immune cells) cellular immunotherapy designed to stimulate a patient’s immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his immune cells.

PROVENGE^® dosing and administration

Treatment with PROVENGE^® includes 3 doses given approximately 2 weeks apart. After 3 infusions The introduction of a solution to a vein, your treatment with PROVENGE is complete.
PROVENGE^® is given by intravenous (IV) infusion in 3 doses, each preceded by a standard cell collection process called leukapheresis The selective removal of leukocytes from the blood, which is then transfused back into the donor. With PROVENGE^®, your leukocytes are removed by means of leukapheresis. It is very important that patients make every effort to stick to the schedule for all of their appointments.
If you miss an infusion of PROVENGE^®, you will likely have to undergo another leukapheresis procedure.

What's New

This is where you can feature something special about the practice, highlight a new service, link to a news article, etc.

PROVENGE® Autologous Cellular Immunotherapy

PROVENGE® dosing and administration

PROVENGE^® Autologous Cellular Immunotherapy

PROVENGE^® dosing and administration